Corpus 1,273 assessed · 1,174 scored · 643 reproduced ≥75 · 169 flagged ·∅ 74.1/100

Publications 2 Datasets 392.5k Experiments 4.7k

Explore

Filters: medium ✕ 1 ✕ clinical-trial ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning. PMID 34575658	J Pers Med	2021	86	L1 86/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning.

PMID 34575658 · J Pers Med · 2021

L1 86/100